Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
APOLO: Atezolizumab + Chemo-RT in Stage IIIA-IIIB NSCLC
NCT04776447Phase 2Completed
- Sponsor
- Fundación GECP
- Start
- Jun 2021
- Primary completion
- Jan 2025
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
A Phase 2 trial of atezolizumab in non-small cell lung cancer (NSCLC), sponsored by Fundación GECP. Started Jun 2021; status: completed.
02
Drugs
atezolizumab
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on NCT04776447.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04776447.